{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T06:32:30Z","timestamp":1790058750971,"version":"4.0.1"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2014,10,20]],"date-time":"2014-10-20T00:00:00Z","timestamp":1413763200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2014,10,20]],"date-time":"2014-10-20T00:00:00Z","timestamp":1413763200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Oncogenesis"],"DOI":"10.1038\/oncsis.2014.37","type":"journal-article","created":{"date-parts":[[2014,10,20]],"date-time":"2014-10-20T13:18:53Z","timestamp":1413811133000},"page":"e122-e122","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Chaetocin antileukemia activity against chronic myelogenous leukemia cells is potentiated by bone marrow stromal factors and overcomes innate imatinib resistance"],"prefix":"10.1038","volume":"3","author":[{"given":"L","family":"Truitt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C","family":"Hutchinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J F","family":"DeCoteau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C R","family":"Geyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,10,20]]},"reference":[{"key":"BFoncsis201437_CR1","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1007\/s12185-010-0615-8","volume":"91","author":"KN Rice","year":"2010","unstructured":"Rice KN, Jamieson CH . Molecular pathways to CML stem cells. Int J Hematol 2010; 91: 748\u2013752.","journal-title":"Int J Hematol"},{"key":"BFoncsis201437_CR2","doi-asserted-by":"publisher","first-page":"724360","DOI":"10.1155\/2013\/724360","volume":"2013","author":"A Hamad","year":"2013","unstructured":"Hamad A, Sahli Z, El Sabban M, Mouteirik M, Nasr R . Emerging therapeutic strategies for targeting chronic myeloid leukemia stem cells. Stem Cells Int 2013; 2013: 724360.","journal-title":"Stem Cells Int"},{"key":"BFoncsis201437_CR3","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.1182\/blood-2010-12-326843","volume":"119","author":"A Hamilton","year":"2012","unstructured":"Hamilton A, Helgason VG, Schemionek M, Zhang B, Myssina S, Allan EK et al. Chronic myeloid leukemia stem cells are not dependent on Bcr-Abl kinase activity for their survival. Blood 2012; 119: 1501\u20131510.","journal-title":"Blood"},{"key":"BFoncsis201437_CR4","doi-asserted-by":"publisher","first-page":"1824","DOI":"10.1182\/blood-2012-02-412890","volume":"121","author":"B Zhang","year":"2013","unstructured":"Zhang B, Li M, McDonald T, Holyoake TL, Moon RT, Campana D et al. Microenvironmental protection of CML stem and progenitor cells from tyrosine kinase inhibitors through N-cadherin and Wnt-\u03b2-catenin signaling. Blood 2013; 121: 1824\u20131838.","journal-title":"Blood"},{"key":"BFoncsis201437_CR5","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1016\/j.bcp.2010.04.003","volume":"80","author":"RR Nair","year":"2010","unstructured":"Nair RR, Tolentino J, Hazlehurst LA . The bone marrow microenvironment as a sanctuary for minimal residual disease in CML. Biochem Pharmacol 2010; 80: 602\u2013612.","journal-title":"Biochem Pharmacol"},{"key":"BFoncsis201437_CR6","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1097\/PPO.0b013e318237e5b7","volume":"17","author":"DW Woessner","year":"2011","unstructured":"Woessner DW, Lim CS, Deininger MW . Development of an effective t herapy for CML. Cancer J 2011; 17: 477\u2013486.","journal-title":"Cancer J"},{"key":"BFoncsis201437_CR7","doi-asserted-by":"publisher","first-page":"4175","DOI":"10.1182\/blood-2012-11-466938","volume":"121","author":"E Bolton-Gillespie","year":"2013","unstructured":"Bolton-Gillespie E, Schemionek M, Klein HU, Flis S, Hoser G, Lange T et al. Genomic instability may originate from imatinib-refractory chronic myeloid leukemia stem cells. Blood 2013; 121: 4175\u20134183.","journal-title":"Blood"},{"key":"BFoncsis201437_CR8","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1172\/JCI35721","volume":"121","author":"AS Corbin","year":"2011","unstructured":"Corbin AS, Agarwal A, Loriaux M, Cortes J, Deininger MW, Druker BJ . Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity. J Clin Invest 2011; 121: 396\u2013409.","journal-title":"J Clin Invest"},{"key":"BFoncsis201437_CR9","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1158\/1535-7163.MCT-07-2331","volume":"7","author":"E Weisberg","year":"2008","unstructured":"Weisberg E, Wright R, McMillin D, Mitsiades C, Ray A, Barrett R et al. Stromal-mediated protection of tyrosine kinase inhibitor-treated BCR-ABL-expressing leukemia cells. Mol Cancer Ther 2008; 7: 1121\u20131129.","journal-title":"Mol Cancer Ther"},{"issue":"1","key":"BFoncsis201437_CR10","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1038\/leu.2014.156","volume":"29","author":"L Schafranek","year":"2014","unstructured":"Schafranek L, Nievergall E, Powell JA, Hiwase DK, Leclercq T, Hughes TP et al. Sustained inhibition of STAT5, but not JAK2, is essential for TKI-induced cell death in chronic myeloid leukemia. Leukemia 2014. e-pub ahead of print 27 June 2014. doi:10.1038\/leu.2014.156.","journal-title":"Leukemia"},{"key":"BFoncsis201437_CR11","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1038\/leu.2009.299","volume":"24","author":"DK Hiwase","year":"2010","unstructured":"Hiwase DK, White DL, Powell JA, Saunders VA, Zrim SA, Frede AK et al. Blocking cytokine signaling along with intense Bcr-Abl kinase inhibition induces apoptosis in primary CML progenitors. Leukemia 2010; 24: 771\u2013778.","journal-title":"Leukemia"},{"key":"BFoncsis201437_CR12","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1038\/nrd4002","volume":"12","author":"C Gorrini","year":"2013","unstructured":"Gorrini C, Harris IS, Mak TW . Modulation of oxidative stress as an anticancer strategy. Nat Rev Drug Discov 2013; 12: 931\u2013947.","journal-title":"Nat Rev Drug Discov"},{"key":"BFoncsis201437_CR13","doi-asserted-by":"publisher","first-page":"4309","DOI":"10.1158\/1078-0432.CCR-12-1424","volume":"19","author":"V Nogueira","year":"2013","unstructured":"Nogueira V, Hay N . Molecular pathways: reactive oxygen species homeostasis in cancer cells and implications for cancer therapy. Clin Cancer Res 2013; 19: 4309\u20134314.","journal-title":"Clin Cancer Res"},{"key":"BFoncsis201437_CR14","doi-asserted-by":"publisher","first-page":"5816","DOI":"10.1182\/blood-2011-01-326025","volume":"117","author":"PS Hole","year":"2011","unstructured":"Hole PS, Darley RL, Tonks A . Do reactive oxygen species play a role in myeloid leukemias? Blood 2011; 117: 5816\u20135826.","journal-title":"Blood"},{"key":"BFoncsis201437_CR15","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1038\/nature10167","volume":"475","author":"L Raj","year":"2011","unstructured":"Raj L, Ide T, Gurkar AU, Foley M, Schenone M, Li X et al. Selective killing of cancer cells by a small molecule targeting the stress response to ROS. Nature 2011; 475: 231\u2013234.","journal-title":"Nature"},{"key":"BFoncsis201437_CR16","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1038\/bjc.2011.522","volume":"106","author":"CR Isham","year":"2012","unstructured":"Isham CR, Tibodeau JD, Bossou AR, Merchan JR, Bible KC . The anticancer effects of chaetocin are independent of programmed cell death and hypoxia, and are associated with inhibition of endothelial cell proliferation. Br J Cancer 2012; 106: 314\u2013323.","journal-title":"Br J Cancer"},{"key":"BFoncsis201437_CR17","doi-asserted-by":"publisher","first-page":"24273","DOI":"10.1074\/jbc.M002094200","volume":"275","author":"M Sattler","year":"2000","unstructured":"Sattler M, Verma S, Shrikhande G, Byrne CH, Pride YB, Winkler T et al. The BCR\/ABL tyrosine kinase induces production of reactive oxygen species in hematopoietic cells. J Biol Chem 2000; 275: 24273\u201324278.","journal-title":"J Biol Chem"},{"key":"BFoncsis201437_CR18","doi-asserted-by":"publisher","first-page":"4015","DOI":"10.1158\/1078-0432.CCR-13-3044","volume":"20","author":"B Sanchez-Sanchez","year":"2014","unstructured":"Sanchez-Sanchez B, Gutierrez-Herrero S, Lopez-Ruano G, Prieto-Bermejo R, Romo-Gonzalez M, Llanillo M et al. NADPH oxidases as therapeutic targets in chronic myeloid leukemia. Clin Cancer Res 2014; 20: 4015\u20134025.","journal-title":"Clin Cancer Res"},{"key":"BFoncsis201437_CR19","doi-asserted-by":"publisher","first-page":"2474","DOI":"10.3109\/10428194.2012.696313","volume":"53","author":"K Flis","year":"2012","unstructured":"Flis K, Irvine D, Copland M, Bhatia R, Skorski T . Chronic myeloid leukemia stem cells display alterations in expression of genes involved in oxidative phosphorylation. Leuk Lymphoma 2012; 53: 2474\u20132478.","journal-title":"Leuk Lymphoma"},{"key":"BFoncsis201437_CR20","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.leukres.2012.11.003","volume":"37","author":"WD Landry","year":"2013","unstructured":"Landry WD, Woolley JF, Cotter TG . Imatinib and Nilotinib inhibit Bcr-Abl-induced ROS through targeted degradation of the NADPH oxidase subunit p22phox. Leuk Res 2013; 37: 183\u2013189.","journal-title":"Leuk Res"},{"key":"BFoncsis201437_CR21","doi-asserted-by":"publisher","first-page":"1669","DOI":"10.18632\/oncotarget.806","volume":"3","author":"W Warsch","year":"2012","unstructured":"Warsch W, Grundschober E, Berger A, Gille L, Cerny-Reiterer S, Tigan AS et al. STAT5 triggers BCR-ABL1 mutation by mediating ROS production in chronic myeloid leukaemia. Oncotarget 2012; 3: 1669\u20131687.","journal-title":"Oncotarget"},{"key":"BFoncsis201437_CR22","doi-asserted-by":"crossref","first-page":"2928","DOI":"10.1182\/blood.V93.9.2928.409k25_2928_2935","volume":"93","author":"M Sattler","year":"1999","unstructured":"Sattler M, Winkler T, Verma S, Byrne CH, Shrikhande G, Salgia R et al. Hematopoietic growth factors signal through the formation of reactive oxygen species. Blood 1999; 93: 2928\u20132935.","journal-title":"Blood"},{"key":"BFoncsis201437_CR23","doi-asserted-by":"publisher","first-page":"2579","DOI":"10.1182\/blood-2006-07-027326","volume":"109","author":"CR Isham","year":"2007","unstructured":"Isham CR, Tibodeau JD, Jin W, Xu R, Timm MM, Bible KC . Chaetocin: a promising new antimyeloma agent with in vitro and in vivo activity mediated via imposition of oxidative stress. Blood 2007; 109: 2579\u20132588.","journal-title":"Blood"},{"key":"BFoncsis201437_CR24","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1089\/ars.2008.2318","volume":"11","author":"JD Tibodeau","year":"2009","unstructured":"Tibodeau JD, Benson LM, Isham CR, Owen WG, Bible KC . The anticancer agent chaetocin is a competitive substrate and inhibitor of thioredoxin reductase. Antioxid Redox Signal 2009; 11: 1097\u20131106.","journal-title":"Antioxid Redox Signal"},{"key":"BFoncsis201437_CR25","doi-asserted-by":"crossref","first-page":"3927","DOI":"10.1182\/blood.V91.10.3927.3927_3927_3934","volume":"91","author":"K Klucher","year":"1998","unstructured":"Klucher K, Lopez D, Daley G . Secondary mutation maintains the transformed state in BaF3 cells with inducible BCR\/ABL expression. Blood 1998; 91: 3927\u20133934.","journal-title":"Blood"},{"key":"BFoncsis201437_CR26","doi-asserted-by":"publisher","first-page":"2578","DOI":"10.1182\/blood-2007-02-073031","volume":"110","author":"S Neering","year":"2007","unstructured":"Neering S, Bushnell T, Sozer S, Ashton J, Rossi R, Wang P-Y et al. Leukemia stem cells in a genetically defined murine model of blast-crisis CML. Blood 2007; 110: 2578\u20132585.","journal-title":"Blood"},{"key":"BFoncsis201437_CR27","first-page":"718","volume":"16","author":"FM Lemoine","year":"1988","unstructured":"Lemoine FM, Humphries RK, Abraham SD, Krystal G, Eaves CJ . Partial characterization of a novel stromal cell-derived pre-B-cell growth factor active on normal and immortalized pre-B cells. Exp Hematol 1988; 16: 718\u2013726.","journal-title":"Exp Hematol"},{"key":"BFoncsis201437_CR28","doi-asserted-by":"publisher","first-page":"s1191","DOI":"10.1038\/leu.2008.74","volume":"22","author":"H Zhang","year":"2008","unstructured":"Zhang H, Trachootham D, Lu W, Carew J, Giles FJ, Keating MJ et al. Effective killing of Gleevec-resistant CML cells with T315I mutation by a natural compound PEITC through redox-mediated mechanism. Leukemia 2008; 22: s1191\u2013s1199.","journal-title":"Leukemia"},{"key":"BFoncsis201437_CR29","doi-asserted-by":"publisher","first-page":"2147","DOI":"10.1182\/blood-2006-08-040022","volume":"109","author":"Y Wang","year":"2007","unstructured":"Wang Y, Cai D, Brendel C, Barett C, Erben P, Manley PW et al. Adaptive secretion of granulocyte-macrophage colony-stimulating factor (GM-CSF) mediates imatinib and nilotinib resistance in BCR\/ABL+ progenitors via JAK-2\/STAT-5 pathway activation. Blood 2007; 109: 2147\u20132155.","journal-title":"Blood"},{"key":"BFoncsis201437_CR30","doi-asserted-by":"publisher","first-page":"1516","DOI":"10.1182\/blood-2013-07-518381","volume":"123","author":"E Traer","year":"2014","unstructured":"Traer E, Javidi-Sharifi N, Agarwal A, Dunlap J, English I, Martinez J et al. Ponatinib overcomes FGF2-mediated resistance in CML patients without kinase domain mutations. Blood 2014; 123: 1516\u20131524.","journal-title":"Blood"},{"key":"BFoncsis201437_CR31","doi-asserted-by":"publisher","first-page":"26692676","DOI":"10.1158\/0008-5472.CAN-13-2797","volume":"74","author":"A Levescot","year":"2014","unstructured":"Levescot A, Flamant S, Basbous S, Jacomet F, Feraud O, Anne Bourgeois E et al. BCR-ABL-Induced deregulation of the IL-33\/ST2 pathway in CD34(+) progenitors from chronic myeloid leukemia patients. Cancer Res 2014; 74: 26692676.","journal-title":"Cancer Res"},{"key":"BFoncsis201437_CR32","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1038\/nature11249","volume":"487","author":"TR Wilson","year":"2012","unstructured":"Wilson TR, Fridlyand J, Yan Y, Penuel E, Burton L, Chan E et al. Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors. Nature 2012; 487: 505\u2013509.","journal-title":"Nature"}],"container-title":["Oncogenesis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/oncsis201437.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/oncsis201437","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/oncsis201437.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,5]],"date-time":"2023-01-05T21:24:04Z","timestamp":1672953844000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/oncsis201437"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,10,20]]},"references-count":32,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2014,10]]}},"alternative-id":["BFoncsis201437"],"URL":"https:\/\/doi.org\/10.1038\/oncsis.2014.37","relation":{},"ISSN":["2157-9024"],"issn-type":[{"value":"2157-9024","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,10,20]]},"assertion":[{"value":"4 July 2014","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 September 2014","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 September 2014","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 October 2014","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}